- Trials with a EudraCT protocol (1,321)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,321 result(s) found for: Latvia.
Displaying page 5 of 67.
EudraCT Number: 2015-004440-19 | Sponsor Protocol Number: CLAM320B2202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regi... | |||||||||||||
Medical condition: Treatment of multidrug-resistant pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004546-26 | Sponsor Protocol Number: VIS410-202 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Visterra, Inc. | |||||||||||||
Full Title: A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects with Uncomplicated Influenza A Infection | |||||||||||||
Medical condition: Influenza A infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000492-33 | Sponsor Protocol Number: BY1023/M3-904 | Start Date*: 2004-09-06 | |||||||||||
Sponsor Name:ALTANA Pharma AG | |||||||||||||
Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis... | |||||||||||||
Medical condition: Gastroesophageal reflux esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000406-30 | Sponsor Protocol Number: 3071-305-020 | Start Date*: 2020-07-13 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis | |||||||||||||
Medical condition: Diabetic Gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003298-90 | Sponsor Protocol Number: OPT-302-1003 | Start Date*: 2018-12-07 | ||||||||||||||||
Sponsor Name:Opthea Ltd | ||||||||||||||||||
Full Title: Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema | ||||||||||||||||||
Medical condition: Persistent central-involved diabetic macular edema | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004098-15 | Sponsor Protocol Number: DS107G-04-UP1 | Start Date*: 2018-01-30 | |||||||||||
Sponsor Name:DS Biopharma | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Se... | |||||||||||||
Medical condition: Moderate to Severe Uremic Pruritus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004571-41 | Sponsor Protocol Number: RBMinCovid19 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Cyxone AB | |||||||||||||
Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19) | |||||||||||||
Medical condition: Coronavirus Disease (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003326-23 | Sponsor Protocol Number: DT-DP-DFU-CR-05 | Start Date*: 2021-07-05 |
Sponsor Name:DermaTools Biotech GmbH | ||
Full Title: A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers | ||
Medical condition: 3. Diabetic foot ulcer treated unsuccessfully for at least 4 weeks with mean diameter between 1.5 and 4 cm after débridement | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) LV (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003991-56 | Sponsor Protocol Number: OPH2003 | Start Date*: 2016-04-15 | |||||||||||
Sponsor Name:IVERIC bio | |||||||||||||
Full Title: A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary t... | |||||||||||||
Medical condition: Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) EE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001634-18 | Sponsor Protocol Number: M602011072 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||||||||||||
Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo... | |||||||||||||||||||||||
Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002168-26 | Sponsor Protocol Number: ML27880 | Start Date*: 2012-01-05 | ||||||||||||||||
Sponsor Name:Roche (Magyarország) Kft. | ||||||||||||||||||
Full Title: OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (E... | ||||||||||||||||||
Medical condition: Open label study of erlotinib (Tarceva®) as single agent first line treatment of patients with locally advanced or metastatic lung adenocarcinoma with activating Epidermal Growth Factor Receptor (E... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000091-14 | Sponsor Protocol Number: FFR102123 | Start Date*: 2004-09-17 |
Sponsor Name:GlaxoSmithKline, S.A | ||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg ... | ||
Medical condition: Perennial allergic rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) SE (Completed) LV (Completed) LT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000406-51 | Sponsor Protocol Number: EMD20001 | Start Date*: 2004-09-16 |
Sponsor Name:GlaxoSmithKline | ||
Full Title: A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment o... | ||
Medical condition: Suspected or Confirmed Gram-negative Severe Sepsis in Adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) ES (Completed) CZ (Completed) LV (Completed) AT (Completed) HU (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006668-25 | Sponsor Protocol Number: BM12H-PSO-03-G-02 | Start Date*: 2022-07-12 | |||||||||||
Sponsor Name:Biocon Biologics UK Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara® in Patients with Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005974-91 | Sponsor Protocol Number: CT-P41_3.1 | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteop... | |||||||||||||
Medical condition: Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003776-13 | Sponsor Protocol Number: ALN-AGT01-003 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled b... | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000696-16 | Sponsor Protocol Number: SEP361-303 | Start Date*: 2019-09-06 | ||||||||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia | ||||||||||||||||||
Medical condition: Schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: LV (Completed) BG (Completed) HR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004493-25 | Sponsor Protocol Number: FFR106080 | Start Date*: 2006-01-12 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg... | ||
Medical condition: Perennial Allergic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003883-28 | Sponsor Protocol Number: SB15-3001 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Samsung Bioepis Co., Ltd. | |||||||||||||
Full Title: A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eyl... | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) HU (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
